Clinical

Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

With no head-to-head trials among the five adjunctive antipsychotics approved for major depressive disorder, payers default to skepticism toward branded options unless indirect comparative evidence proves added value beyond cost.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Stephen "Fred" Divers, MD, previews PCOC 2026, including his session on the Oncology Care Index and the gap in AI adoption in oncology.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.

Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.

The panelists examined the hurdles of practicing without local backup.

From host-directed therapies to inhaled drug delivery, Dr. Losier maps the research priorities that could finally match the right MAC and NTM treatment to the right patient.

Led by the moderator, the expert neurology and primary care panelists examined what an ideal training curriculum looks like.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.

Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Led by the moderator, the panelists/expert mental health experts examined key patient-level factors driving selection among the five adjunctive agents — including weight status, sleep disturbance, and general medication sensitivity — with Wilkinson noting a preference for lumateperone given its lack of weight gain and quetiapine for patients needing help with sedation who aren't already overweight, while Bhide observed these are exactly the clinical factors payers would want documented under utilization management.

Led by the moderator, the expert mental health experts examined network meta-analysis data comparing weight gain and akathisia across the five agents, with Rhee noting lumateperone did not differ from placebo on weight gain while the other four agents showed increased risk, and cautioning that these exploratory findings warrant careful interpretation given limited clinical data.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

Inebilizumab's twice-yearly CD19 dosing directly targets antibody-producing cells; trial enrollment used disease activity, not treatment failure.

Employers can advance patient-centered oncology care through proactive benefits, quality data, navigation, and tailored support, Amanda Green, MPH, said.

A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.

Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.